Serum visfatin levels do not increase in post-menopausal women with metabolic syndrome
Künye
Guducu N, Isci H, Gormus U, Yigiter AB, Dunder I. Serum visfatin levels do not increase in post-menopausal women with metabolic syndrome. Journal of Endocrinological Investigation. 2013; 36(3): 157-161. doi: 10.1007/BF03346752Özet
Background: The aim of this study was to determine the serum visfatin levels in post-menopausal (PM) women with and without metabolic syndrome (MS) and to understand the correlation between serum visfatin levels and various other hormonal and metabolic parameters. Materials-Methods: We conducted a prospective cross-sectional study including 17 PM women with MS and a control group of 51 PM women without MS. MS was defined according to the National Cholesterol Education Program Adult Treatment Panel III. Results: Women with MS had statistically significantly higher fasting blood glucose, HDL, triglycerides, insulin, homeostasis model assessment of insulin resistance, and SHBG levels when compared to women without MS. Estradiol, high sensitivity C-reactive protein, and free testosterone levels were higher in the MS group, but there was no statistically significant difference between the two groups. Visfatin levels did not differ between the two groups. There was no correlation between serum visfatin levels and other parameters.Conclusions: There was no association between serum visfatin levels and MS in PM women.